Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

AstraZeneca's Hard To Control Hypertension Drug Advances, With FDA Decision Expected In 2026

Astrazeneca

On Tuesday, the U.S. Food and Drug Administration accepted AstraZeneca Plc's (NASDAQ:AZN) New Drug Application (NDA) for baxdrostat for adult patients with hard-to-control (uncontrolled or treatment-resistant) hypertension as an add-on to other antihypertensive medicines.

There are 1.4 billion people worldwide living with hypertension. In the US, approximately 50% of patients living with hypertension on multiple treatments do not have their blood pressure under control.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.